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In 2017 the American College of Cardiology (ACC), the American Heart Association (AHA) 
and nine other American societies released guidelines for the prevention, detection, 
evaluation and management of high blood pressure (BP) in adults.1   
These guidelines are perhaps the most controversial set of US guidelines – even more so 
than those attributed to some of the committee set up to produce “JNC 8” in 2014.2 
Before discussing the various controversial aspects of the ACC/AHA guidelines, ISH would 
like to congratulate the authors on three counts.  Firstly, emphasis was placed on the 
appropriate technique of BP measurements and the increased need for out-of-office BP 
measurement.  Secondly the value of risk assessment was recognised and introduced for the 
first time in US guidelines and finally, perhaps in part due to the controversial nature of the 
document, awareness of the importance of BP as a global cause of morbidity and mortality 
has been raised. 
The central controversy around which several others arise is the redefining of hypertension 
– as a systolic BP >130 mmHg or a diastolic BP >80 mmHg.  Whilst there is a clear dose-
response relationship between increasing BP levels and adverse cardiovascular (CV) 
outcomes3, this pre-empts the ability, based on predicting CV events, of precisely defining 
‘hypertension’.  However, the pragmatic definition proposed by Geoffrey Rose decades ago 
should perhaps be considered – viz: “that level of BP above which investigation and 
management does more good than harm”.4   Does the new BP level proposed in the 
ACC/AHA guidelines fully satisfy that criterion?  Perhaps not.  To date the relevant data are 
inconsistent and hence controversial. 
The problem arises because the definition of hypertension, treatment thresholds and BP 
targets should be inexorably linked, if we are to be logical about diagnosis and treatment. 
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It seems likely that the new ACC/AHA definition arose, in large part, from the results of the 
SPRINT trial.5  The ACC/AHA authors have apparently modified the systolic BP target of <120 
mmHg established as superior in the SPRINT trial, in light of concerns over the method of 
measurement used6 and set a systolic BP of <130 mmHg as the target BP.  This makes the 
setting of the treatment threshold difficult unless target and threshold are to be dissociated.  
Inevitably, if threshold and target unite, the definition of hypertension follows on as a 
systolic BP >130 mmHg. 
However, as a multinational society whose role is to present a global perspective, the ISH is 
concerned at the impact of redefining hypertension in countries around the world – 
particularly those of low and middle income. 
The reality for most of the world is that BP control rates (to <140 mmHg and <90 mmHg) are 
<15%.7 Surely this is not the time to impose a huge increase in hypertension prevalence by 
redefining it, particularly when the data regarding optimal targets are inconsistent and 
hence remain subject to debate.8,9,10,11 
In an article written prior to publication of the ACC/AHA guidelines, the ISH provided a 
global perspective on BP thresholds and targets.12  We concluded that whilst the data were 
(and still are) by no means definitive, in an ideal world, where resources allow, and in the 
interest of simplicity a systolic target of 130 mmHg could reasonably be set for people with 
or without diabetes.  However, we acknowledged that thresholds as low as 140 mmHg may 
be inappropriately low, which is supported by some current guidelines,13,14 that recommend 
that treatment may not be indicated for low risk patients with a systolic BP below 160 
mmHg. 
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Pending more definitive information we believe focus should be placed on improving BP 
awareness15 and once hypertension is diagnosed, ensuring that effective, low-cost, 
evidence-based medicines are available to lower BP to current targets (<140/90 mmHg).4,16  
Only as resources allow might the systolic target of 130 mmHg be invoked and then possibly 
only for those at highest CV risk. 
We believe that even through the ideal systolic BP target may be 130 mmHg the standard 
definition of hypertension should not change and to square the circle of having a mismatch 
between definition and target, those with systolic BPs between 130-139 mmHg should be 
labelled as “high normal” or “pre-hypertensive” (as per the JNC 7 guidelines).17  All such 
people should receive non-pharmacological advice and as resources allow drug therapy 
could be initiated for those at highest risk including those with a history of established CV 
disease. 
The global uptake of the newly-proposed hypertension definition seems unlikely and may be 
inappropriate.  Even in the US, two major societies, the American Academy for Family 
Physicians and the American College of Physicians have raised concerns about potential 
harm associated with implementing the ACC/AHA guidelines18 and others have suggested 
that no likely benefit in terms of cost-efficacy might accrue.19 
Elsewhere around the world, recommended BP levels differed in eight of 14 comparisons of 
thresholds and targets for patient subgroups in ACC/AHA versus Canadian guidelines20 and 
in the Australian NHF guidelines21 all 11 direct comparisons of thresholds and targets differ 
from those in the ACC/AHA guidelines.  This is not to say that any of these three sets of 
guidelines are correct, but rather to highlight that there is no consensus about these data. 
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The concerns raised regarding the new ACC/AHA definition of hypertension and the 
associated clinical fallout include the dangers of inappropriately labelling people as 
hypertensive and thereby causing anxiety,22 and over-inflated hypertension treatment in 
low risk younger people (especially women) who get caught up in the newly-enhanced 
‘hypertensive’ population for whom evidence of treatment benefit is not yet established.23 
Other issues that we believe reflect the lack of suitability of the ACC/AHA guidelines for 
exportation to most of the world, include the recommended method of unattended clinic 
BP measurement which, whilst it has undoubted benefits, is aspirational in most of the 
world.  In addition, the idea that adults with “stage 2 hypertension” – hitherto defined as 
mild or stage 1 hypertension – should be seen within one month of diagnosis and at that 
time receive two agents as “first-line” therapy lacks a robust evidence base.  Furthermore, 
that follow-up for such patients should occur in one month after initiating therapy is an 
unrealistic expectation for the vast majority of the world and, given that most agents - alone 
or in combination - usually produce maximal BP-lowering effects well after four weeks is 
probably unnecessarily soon. 
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Summary: 
On the basis of currently available evidence, 
1. We welcome the increased emphasis on out-of-office BP measurement which the 
ACC/AHA guidelines provide, but advise caution on the reported equivalence levels 
by type of measurement. 
2. We support the use of risk assessment recommended in the ACC/AHA guidelines but 
note that the levels recommended as defining high risk do not accurately match 
those used in SPRINT. 
3. We welcome the increased awareness about the importance of raised BP which the 
ACC/AHA guidelines have raised. 
4. We suggest that in the global context, the definition of hypertension should remain 
as systolic BP >140 mmHg and/or diastolic BP >90 mmHg. 
5. We believe that ideal systolic BP targets for those with or without diabetes should 
probably be 130 mmHg.  However, people with systolic BP in the range 130-139 
mmHg should receive non-pharmacological advice, and only where resources allow 
and for those at high CV risk should drug therapy be considered for such people.   
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